The number of lawsuits against AndroGel, filed by patients that have suffered heart attacks and strokes, was so high that a panel of judges decided to consolidate all the cases under one courthouse’s roof.
The judicial panel’s decision to have all the cases heard by U.S. District Judge Matthew Kennelly came as good news to AndroGel’s makers, AbbVie. If the decision had not been made, the pharmaceutical company may have been overwhelmed by defending themselves in courthouses all across the country.
The $1.6 billion/year testosterone industry has come under fire for medical reports that link testosterone replacement therapy with a 29% increased risk of death by heart attack or stroke. The FDA has responded to the reports by promising to re-investigate the group of drugs.
The pharmaceutical companies that produce testosterone prescriptions have been accused by some of unethical marketing campaigns. Critics have said that the Low T campaign has mislead men into thinking drugs like AndroGel, Axiron, and Testim will solve problems that the FDA has, in fact, not approved testosterone use for. The successful campaign has lined the pockets of pharmaceutical execs while endangering the lives of many men.